Completed PHASE3 INTERVENTIONAL 2-arm NCT02619149

Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis (AVAC)

Sponsor: Karolinska Institutet

Interventions Piperacillin-tazobactam combination product Saline solution

Updated 6 times since 2017 Last updated: Mar 5, 2018 Started: Mar 31, 2009 Primary completion: Dec 31, 2017 Completion: Jan 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02619149, this PHASE3 trial focuses on Cholecystitis, Acute and remains completed. Sponsored by Karolinska Institutet, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Mar 2018 — Jun 2018 [monthly]

Completed PHASE3

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Mar 2018 [monthly]

Recruiting PHASE3

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Karolinska Institutet

Data source: Karolinska Institutet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden